NCT00437255

Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis

An Evaluation of the Efficacy, Safety, Preference and Duration of Response of Clobex® (Clobetasol Propionate) Spray and Taclonex® (Calcipotriene 0.05%/Betamethasone Dipropionate 0.064%) Ointment in Subjects With Stable Plaque Psoriasis

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 122 (actual)
• Sponsor: Galderma R&D · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Evaluate the efficacy of Clobex® Spray as compared to Taclonex® Ointment in terms of Overall Disease Severity and Investigator Global Assessment.

Detailed description

Same as above.

Conditions

• Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	Clobetasol Propionate, 0.05%	Topical, twice daily for 4 weeks
DRUG	Calcipotriene and betamethasone dipropionate ointment	Topical, once daily

Timeline

• Start date: 2006-08-01
• Primary completion: 2007-06-01
• Completion: 2007-06-01
• First posted: 2007-02-19
• Last updated: 2022-07-29

Locations

4 sites across 1 country: United States